Research by the Connecticut Gastroenterology Institute at Bristol Hospital Shows Promising New Treatments for Patients with the Irritable Bowel Syndrome
Landmark Study Featured in 1/6/11 Issue of New England Journal of Medicine
BRISTOL, Conn.--(BUSINESS WIRE)--Jan 6, 2011 - A team of researchers including Bristol Hospital's Connecticut Gastroenterology Institute today had their landmark study on the Irritable Bowel Syndrome (IBS) published in the New England Journal of Medicine.
IBS is the most common gastrointestinal disorder in the United States, affecting more than 15 percent of the population. The study concludes that, for the first time, there are new effective treatments for the tens of millions of Americans who suffer from IBS.
Salam F. Zakko, MD, FACP is the Executive Director of the Connecticut Gastroenterology Institute at Bristol Hospital where he conducted his research. Other research centers that participated in the study include: Cedars-Sinai Medical Center, Harvard Medical School, Beth Israel Deaconess Medical Center, the University of Michigan Health System, University of North Carolina at Chapel Hill whose principal investigators, along with Dr. Zakko, are authors of the landmark study.
The Connecticut Gastroenterology Institute is the only center in Connecticut to offer the unique, leading-edge research and advanced treatment options available in the field of gastroenterology.
Dr. Zakko and his team are internationally recognized in the field and have successfully treated thousands of patients with symptoms of IBS from throughout the region over the past twenty years. They have pioneered many state-of-the-art, non-invasive procedures, including the use of pill endoscopy to diagnose small bowel disorders, and the use of the SLEUTH total reflux monitor for patients with non-acid reflux.
“This is wonderful news for those patients with IBS who have not been able to find lasting and effective relief,” stated Dr. Zakko. He adds, “This preliminary study paves the way for more research that can lead to a cure, instead of just treating the symptoms for IBS. Bristol Hospital offered my team and I the environment necessary to conduct advanced gastroenterology research that no other hospital in the area was able to provide.”
“Research at this level is unprecedented at community hospitals, so we're very proud of the work Dr. Zakko continues to conduct here at Bristol Hospital,” stated Kurt A. Barwis, President and Chief Executive Officer of Bristol Hospital. “More important, though, is the positive difference Dr. Zakko has made in the lives of his patients. His patient care and results are truly representative of the extraordinary care we provide our patients everyday.”
About Bristol Hospital and Healthcare Group
Founded in 1921, Bristol Hospital and Health Care Group (˜BHHCG') is committed to providing the best patient experience in the region and enhancing the well being of the greater Bristol, Connecticut community. BHHCG, is a fully integrated health care delivery system providing a full continuum of services including a 134-bed acute care hospital, a skilled nursing facility, a multi-specialty physician practice, a home health care and hospice program, physical therapy and wound care center, counseling and wellness centers, and an Ambulance Service.
Link to New England Journal of Medicine article: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1004409
Contact: Bristol Hospital
Kathleen Buckley, 860-585-3837
Vice President, Strategic Planning and Business Development
Posted: January 2011